| 1. |
- Naver, Lars, et al.
(författare)
-
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2007
- 2008
-
Ingår i: Scandinavian Journal of Infectious Diseases. - : Informa UK Limited. - 1651-1980 .- 0036-5548. ; 40:6-7, s. 451-461
-
Forskningsöversikt (refereegranskat)abstract
- Prophylaxis and treatment with antiretroviral drugs, a consequent low viral load, and the use of elective Caesarean section, are factors that radically decrease the risk of HIV transmission from mother to child during pregnancy and delivery. The availability of new antiretroviral drugs, updated general treatment guidelines and increasing knowledge of the importance of drug resistance, have necessitated recurrent revisions of the recommendations for 'Prophylaxis and treatment of HIV-1 infection in pregnancy'. For these reasons, The Swedish Reference Group for Antiviral Therapy (RAV) has, at an expert meeting on May 4, 2007, once more updated the treatment recommendations of 1999, 2002 and 2005, which were defined in cooperation with the Swedish Medical Products Agency (Lakemedelsverket). This new text takes the recently updated general HIV treatment recommendations into account. Furthermore, the very low risk of HIV transmission when the mother is treated with combination antiretroviral therapy, has undetectable levels of viraemia and no obstetric risk factors, has been considered in the recommendations concerning the mode of delivery. Finally, the recommendations for monitoring of infants born to HIV-infected mothers have been modified. The recommendations are evidence graded in accordance with the Oxford Centre for Evidence Based Medicine, 2001 (see http://www.cebm.net/levels_of_evidence.asp#levels).
|
|
| 2. |
- Naver, Lars, et al.
(författare)
-
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010
- 2011
-
Ingår i: Scandinavian Journal of Infectious Diseases. - : Informa UK Limited. - 1651-1980 .- 0036-5548. ; 43:6-7, s. 411-423
-
Forskningsöversikt (refereegranskat)abstract
- Prophylaxis and treatment with antiretroviral drugs and the use of elective caesarean section have resulted in a very low mother-to-child transmission of human immunodeficiency virus (HIV) during recent years. The availability of new antiretroviral drugs, updated general treatment guidelines and increasing knowledge of the importance of drug resistance, have necessitated regular revisions of the "Prophylaxis and treatment of HIV-1 infection in pregnancy" recommendations. For these reasons, The Swedish Reference Group for Antiviral Therapy (RAV) updated the 2007 recommendations at an expert meeting that took place on 25 March 2010. The most important revisions from the previous recommendations are: (1) it is recommended that treatment during pregnancy starts at the latest at gestational week 14-18; (2) ongoing efficient treatment at confirmed pregnancy may, with a few exceptions, be continued; (3) lopinavir/r and atazanavir/r are equally recommended protease inhibitors; (4) if maternal HIV RNA is >50 copies/ml close to delivery, a planned caesarean section, intravenous zidovudine, oral nevirapine for the mother and post-exposure prophylaxis for the infant with 3 antiretroviral drugs are recommended; (5) for delivery at <34 gestational weeks, intravenous zidovudine and oral nevirapine for the mother and at 48-72 h for the infant is recommended, in addition to other prophylaxis; (6) intravenous zidovudine is not recommended when HIV RNA is <50 copies/ml and a caesarean section is performed; (7) it is recommended that prophylaxis for the infant is started within 4 h; (8) prophylactic zidovudine for the infant may be administered twice daily instead of 4 times a day, as was the case previously; and (9) the number of sampling occasions for the infant has been decreased.
|
|
| 3. |
- Lindkvist, Rose Marie, et al.
(författare)
-
Brief admission by self-referral as an add-on to usual care for individuals with self-harm at risk of suicide : cost-effectiveness and 4-year health-economic consequences after a Swedish randomized controlled trial
- 2024
-
Ingår i: Nordic Journal of Psychiatry. - 0803-9488.
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Brief Admission by self-referral (BA) is a crisis-management intervention standardized for individuals with self-harm at risk of suicide. We analyzed its health-economic consequences. Materials and methods: BA plus treatment as usual (TAU) was compared with TAU alone in a 12-month randomized controlled trial with 117 participants regarding costs for hospital admissions, coercive measures, emergency care and health outcomes (quality-adjusted life years; QALYs). Participants were followed from 12 months before baseline to up to five years after. Results: Over one year BA was associated with a mean annual cost reduction of 4800 or incremental cost of 4600 euros, depending on bed occupancy assumption. Cost-savings were greatest for individuals with >180 admission days in the year before baseline. In terms of health outcomes BA was associated with a QALY gain of 0.078. Uncertainty analyses indicated a significant QALY gain and ambiguity in costs, resulting in BA either dominating TAU or costing 59 000 euros per gained QALY. Conclusion: BA is likely to produce QALY gains for individuals living with self-harm and suicidality. Cost-effectiveness depends on targeting high-need individuals and comparable bed utilization between BA and other psychiatric admissions. Future research should elaborate the explanatory factors for individual variations in the usage and benefit of BA.
|
|
| 4. |
- Naver, Lars, et al.
(författare)
-
Prophylaxis and treatment of HIV infection in pregnancy, Swedish guidelines 2024
- 2024
-
Ingår i: INFECTIOUS DISEASES. - 2374-4235 .- 2374-4243. ; 56:8, s. 657-668
-
Tidskriftsartikel (refereegranskat)abstract
- In May 2024, the Swedish Reference Group on Antiviral Therapy updated the guidelines on management of HIV infection in pregnancy. The most important recommendations and revisions were: (i) ART during pregnancy should be started as early as possible and continue after delivery; (ii) Suppressive ART should normally not be modified; (iii) The treatment target of HIV RNA <20 copies/ml remains; (iv) Dolutegravir/emtricitabine/tenofovir DF is the first-line drug combination also in pregnant women and women planning pregnancy; (v) There is no evidence of an increased risk of neural tube defects associated with dolutegravir; (vi) Mode of delivery for women with effective ART and HIV RNA <200 copies/ml should follow standard obstetric procedures; (vii) Caesarean section is recommended if HIV RNA >= 200 copies/ml; (viii) Scalp electrode, foetal blood sampling and/or vacuum delivery should be used on strict indications, but does not necessitate intensified infant prophylaxis; (ix) Management and mode of delivery in case of premature or full-term rupture of membranes should follow standard obstetric procedures; (x) Recommended infant antiretroviral prophylaxis has been updated; (xi) The duration of infant antiretroviral prophylaxis (gestational age >= 35 weeks and mother on effective ART and HIV RNA <200 copies/ml) has been changed from 4 to 2 weeks; (xii) Infants born to women with HIV RNA >= 200 copies/ml should receive 4 weeks of combination prophylaxis; (xiii) Fertility evaluation and assisted reproduction should be offered to women on suppressive ART according to the same principles as for other women; (xiv) Women living with HIV should still be advised against breastfeeding; (xv) Women who nevertheless opt to breastfeed should be offered intensified support and follow-up.
|
|
| 5. |
- Westling, Katarina, et al.
(författare)
-
Bartonella henselae antibodies after cat bite
- 2008
-
Ingår i: Emerging Infectious Diseases. - : Centers for Disease Control and Prevention (CDC). - 1080-6040 .- 1080-6059. ; 14:12, s. 1943-1944
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
- Westling, Katarina, et al.
(författare)
-
Swedish guidelines for diagnosis and treatment of infective endocarditis.
- 2007
-
Ingår i: Scandinavian journal of infectious diseases. - : Informa UK Limited. - 0036-5548 .- 1651-1980. ; 39:11-12, s. 929-46
-
Tidskriftsartikel (refereegranskat)abstract
- Swedish guidelines for diagnosis and treatment of infective endocarditis (IE) by consensus of experts are based on clinical experience and reports from the literature. Recommendations are evidence based. For diagnosis 3 blood cultures should be drawn; chest X-ray, electrocardiogram, and echocardiography preferably transoesophageal should be carried out. Blood cultures should be kept for 5 d and precede intravenous antibiotic therapy. In patients with native valves and suspicion of staphylococcal aetiology, cloxacillin and gentamicin should be given as empirical treatment. If non-staphylococcal etiology is most probable, penicillin G and gentamicin treatment should be started. In patients with prosthetic valves treatment with vancomycin, gentamicin and rifampicin is recommended. Patients with blood culture negative IE are recommended penicillin G (changed to cefuroxime in treatment failure) and gentamicin for native valve IE and vancomycin, gentamicin and rifampicin for prosthetic valve IE, respectively. Isolates of viridans group streptococci and enterococci should be subtyped and MIC should be determined for penicillin G and aminoglycosides. Antibiotic treatment should be chosen according to sensitivity pattern given 2-6 weeks intravenously. Cardiac valve surgery should be considered early, especially in patients with left-sided IE and/or prosthetic heart valves. Absolute indications for surgery are severe heart failure, paravalvular abscess, lack of response to antibiotic therapy, unstable prosthesis and multiple embolies. Follow-up echocardiography should be performed on clinical indications.
|
|
| 7. |
- Westling, Katarina, et al.
(författare)
-
Toxoplasmosis not transmitted by cat bite, but high prevalence of antibodies to toxoplasma gondii in patients bitten by their own cat
- 2010
-
Ingår i: Scandinavian Journal of Infectious Diseases. - : Informa UK Limited. - 0036-5548 .- 1651-1980. ; 42:9, s. 687-690
-
Tidskriftsartikel (refereegranskat)abstract
- The aims of the study were to investigate the prevalence of antibodies to Toxoplasma gondii in a group of patients bitten by cats, and also to determine if toxoplasmosis can be transferred by cat bite. Seventy-two patients who attended the emergency wards at 3 hospitals in Stockholm, Sweden, due to infection by cat bite, were investigated for specific IgM and IgG antibodies to T. gondii in the acute phase, as well as in the convalescent phase about 2 weeks later. Specific IgG antibodies to T. gondii (> or =8 IU/ml) were found in 17/72 patients (24%) in the acute phase. No case of seroconversion occurred. Patients who were bitten by their own cat had positive antibody titres to T. gondii significantly more often than those bitten by a foreign cat; 30% and 5%, respectively (p = 0.02). This suggests that regular contact with cats may contribute to the transmission of the parasite.
|
|
| 8. |
- Westling, Katarina
(författare)
-
Viridans group streptococci septicaemia and endocarditis : molecular diagnostics, antibiotic susceptibility and cinical aspects
- 2005
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Viridans group streptococci (VGS) are inhabitants in the oral cavity and in the gastrointestinal tract. They cause severe infections, they are responsible for up to 39 % of the cases of septicaemia in neutropenic patients with haematological diseases and cause infective endocarditis (IE), mainly in patients with native valves and previous heart disease. Different species cause different clinical picture, therefore the identification of the species is important. The conventional methods for identification of VGS strains, Strep API and API ZYM have not been optimal. A reduced antibiotic susceptibility to penicillin in VGS has developed during the last years, primarily for patients with haematological diseases. In the present studies we have investigated the rate of infective endocarditis and risk factors, in immunocompetent and immunocompromised patients with septicaemia. We have identified species of VGS septicaemia with old and new diagnostic methods and analysed the antibiotic susceptibility for penicillin and other antimicrobial agents in the oral cavity and blood cultures. In these studies we found that infective endocarditis was rare in patients with haematological diseases, in this group of patients VGS species as Streptococcus mitis and Streptococcus oralis dominated. When we used rnpB sequencing and PCR, it was possible to identify species of VGS that earlier has been difficult to classify. In patients with infective endocarditis, strains for the Streptococcus sanguinis group dominated, when using rnpB sequencing we also found Streptococcus gordonii and Streptococcus oralis strains in these patients. We found a reduced susceptibility to pencillin in 18 % (MIC ≥ 0.25 μg/ml) of the VGS isolates in 1998-2003, that is lower compared to studies from Canada where 37 % of the strains had a reduced susceptibility to pencillin. The antibiotic resistance to VGS was increased compared to 1992-1997, however different methods had been used. The highest rate of pencillin resistance in this study was found in oral swabs from haematological patients where 25% of the VGS isolates were resistant to penicillin (MIC ≥ 4.0 μg/ml), which was higher that we had expected. This is an important observation because the oral cavity has been described as a genetic reservoir for transferring resistance genes from VGS to Streptococcus pneumoniae. We also found that 19% of the isolates had a reduced susceptibility to erythromycin (MIC ≥ 0.5 μg/ml) and 80% of these strains harbored mefA and 40 % ermB. The VGS strains in 1998-2003 had a reduced susceptibility to ciprofloxacin; which has previously been used as antibiotic prophylaxis in neutropenic patients but is not generally recommended because of emergence of resistance. Vancomycin had a high susceptibility to VGS but it should only be used as empiric therapy for severe cases and for resistant strains because of the emergence of resistance. New antimicrobial agent as linezolid seems susceptible but should be saved for cases of antibiotic resistance.
|
|
